Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management.

Prasad R, Singh A, Balasubramanian V, Gupta N.

Indian J Med Res. 2017 Mar;145(3):271-293. doi: 10.4103/ijmr.IJMR_177_16. Review.

2.

Structure-Based Optimization of Pyridoxal 5'-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in Mycobacterium tuberculosis.

Liu F, Dawadi S, Maize KM, Dai R, Park SW, Schnappinger D, Finzel BC, Aldrich CC.

J Med Chem. 2017 Jul 13;60(13):5507-5520. doi: 10.1021/acs.jmedchem.7b00189. Epub 2017 Jun 22.

PMID:
28594172
3.

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia.

Elmi OS, Hasan H, Abdullah S, Mat Jeab MZ, Ba Z, Naing NN.

Malays J Med Sci. 2016 Jul;23(4):17-25. doi: 10.21315/mjms2016.23.4.3. Epub 2016 Jun 30.

4.

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, Viiklepp P;  on behalf of the Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment.

Eur Respir J. 2016 Oct;48(4):1160-1170. doi: 10.1183/13993003.00462-2016. Epub 2016 Sep 1.

5.

Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan.

Khan MA, Mehreen S, Basit A, Khan RA, Jan F, Ullah I, Ihtesham M, Khan A, Ullah U, Javaid A.

Saudi Med J. 2015 Dec;36(12):1463-71. doi: 10.15537/smj.2015.12.12155.

6.

The multidrug-resistant tuberculosis threat: old problems and new solutions.

Sotgiu G, D'Ambrosio L, Centis R, Mura I, Castiglia P, Spanevello A, Migliori GB.

J Thorac Dis. 2015 Sep;7(9):E354-60. doi: 10.3978/j.issn.2072-1439.2015.09.21. No abstract available.

7.

'Z(S)-MDR-TB' versus 'Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility.

Zhang Y, Chiu Chang K, Leung CC, Wai Yew W, Gicquel B, Fallows D, Kaplan G, Chaisson RE, Zhang W.

Emerg Microbes Infect. 2012 Jul;1(7):e5. doi: 10.1038/emi.2012.18. Epub 2012 Jul 25. Review.

8.

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB.

Clin Infect Dis. 2014 Nov 15;59(10):1364-74. doi: 10.1093/cid/ciu619. Epub 2014 Aug 5.

9.

Extensively drug-resistant tuberculosis: epidemiology and management.

Matteelli A, Roggi A, Carvalho AC.

Clin Epidemiol. 2014 Apr 1;6:111-8. doi: 10.2147/CLEP.S35839. eCollection 2014. Review.

10.

Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.

Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R.

Lancet Respir Med. 2014 Apr;2(4):321-38. doi: 10.1016/S2213-2600(14)70031-1. Epub 2014 Mar 24. Review.

11.

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

Dartois V.

Nat Rev Microbiol. 2014 Mar;12(3):159-67. doi: 10.1038/nrmicro3200. Epub 2014 Feb 3. Review.

12.

TBNET - Collaborative research on tuberculosis in Europe.

Giehl C, Lange C, Duarte R, Bothamley G, Gerlach C, Cirillo DM, Wagner D, Kampmann B, Goletti D, Juers T, Sester M.

Eur J Microbiol Immunol (Bp). 2012 Dec;2(4):264-74. doi: 10.1556/EuJMI.2.2012.4.4. Epub 2012 Dec 11.

13.

Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis.

Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC.

Clin Infect Dis. 2014 Feb;58(3):381-91. doi: 10.1093/cid/cit643. Epub 2013 Sep 24. Review.

14.

WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.

Chang KC, Yew WW, Tam CM, Leung CC.

Antimicrob Agents Chemother. 2013 Sep;57(9):4097-104. doi: 10.1128/AAC.00120-13. Epub 2013 Jun 17. Review.

15.

Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review.

Arentz M, Pavlinac P, Kimerling ME, Horne DJ, Falzon D, Schünemann HJ, Royce S, Dheda K, Walson JL; ART study group.

PLoS One. 2012;7(11):e47370. doi: 10.1371/journal.pone.0047370. Epub 2012 Nov 5. Review.

16.

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado MG, Keshavjee S, DeRiemer K, Centis R, D'Ambrosio L, Lange CG, Bauer M, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.

Eur Respir J. 2013 Jul;42(1):156-68. doi: 10.1183/09031936.00134712. Epub 2012 Oct 25.

17.

Challenges and controversies in defining totally drug-resistant tuberculosis.

Cegielski P, Nunn P, Kurbatova EV, Weyer K, Dalton TL, Wares DF, Iademarco MF, Castro KG, Raviglione M.

Emerg Infect Dis. 2012 Nov;18(11):e2. doi: 10.3201/eid1811.120526.

18.

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.

PLoS Med. 2012;9(8):e1001300. Epub 2012 Aug 28.

19.

Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.

Chang KC, Leung CC, Yew WW, Leung EC, Leung WM, Tam CM, Zhang Y.

Antimicrob Agents Chemother. 2012 Nov;56(11):5465-75. doi: 10.1128/AAC.01300-12. Epub 2012 Aug 6.

20.

Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.

Cavanaugh JS, Kazennyy BY, Nguyen ML, Kiryanova EV, Vitek E, Khorosheva TM, Nemtsova E, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1069-74. doi: 10.5588/ijtld.11.0696. Epub 2012 Jun 11.

Supplemental Content

Support Center